HomeCompareVPAHF vs VIG

VPAHF vs VIG: Dividend Comparison 2026

VPAHF yields 270.27% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VPAHF wins by $759.40M in total portfolio value
10 years
VPAHF
VPAHF
● Live price
270.27%
Share price
$0.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$759.43M
Annual income
$439,524,286.02
Full VPAHF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — VPAHF vs VIG

📍 VPAHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVPAHFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VPAHF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VPAHF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VPAHF
Annual income on $10K today (after 15% tax)
$22,972.97/yr
After 10yr DRIP, annual income (after tax)
$373,595,643.12/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, VPAHF beats the other by $373,595,494.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VPAHF + VIG for your $10,000?

VPAHF: 50%VIG: 50%
100% VIG50/50100% VPAHF
Portfolio after 10yr
$379.73M
Annual income
$219,762,230.61/yr
Blended yield
57.87%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VPAHF buys
0
VIG buys
0
No recent congressional trades found for VPAHF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVPAHFVIG
Forward yield270.27%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$759.43M$32.3K
Annual income after 10y$439,524,286.02$175.21
Total dividends collected$726.21M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VPAHF vs VIG ($10,000, DRIP)

YearVPAHF PortfolioVPAHF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$37,727$27,027.03$11,301$160.59+$26.4KVPAHF
2$135,662$95,294.33$12,752$162.91+$122.9KVPAHF
3$465,409$320,250.45$14,370$165.02+$451.0KVPAHF
4$1,524,778$1,026,790.34$16,176$166.93+$1.51MVPAHF
5$4,775,420$3,143,907.74$18,188$168.67+$4.76MVPAHF
6$14,311,885$9,202,185.51$20,432$170.25+$14.29MVPAHF
7$41,088,348$25,774,630.79$22,933$171.68+$41.07MVPAHF
8$113,120,635$69,156,102.86$25,720$172.98+$113.09MVPAHF
9$298,977,565$177,938,485.31$28,827$174.15+$298.95MVPAHF
10$759,430,280$439,524,286.02$32,288$175.21+$759.40MVPAHF

VPAHF vs VIG: Complete Analysis 2026

VPAHFStock

Volpara Health Technologies Limited provides breast imaging analytics software products in New Zealand. The company offers Volpara Analytics, a software that optimize breast cancer screening operations; Volpara Live, which provides instant patient-based image quality feedback; Volpara Lung, a patient management software that streamlines lung screening workflow; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses TC8 to calculate patients' risk of developing breast cancer; Volpara Risk Pathways, a program for identifying and managing high-risk breast cancer screening patients; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products. In addition, the company provides TruDensity, a Volpara clinical function; TruPGMI, a Volpara clinical function, which uses artificial intelligence to automatically and objectively assess the positioning of the patient and resulting image quality; TruPressure, a Volpara clinical function, which determines whether the compression pressure applied by the radiographer is in the sweet spot that yields quality images, minimal radiation exposure, and the least discomfort; and TruRadDose, a Volpara clinical function which analyses the radiation dose delivered to patients based on their breast density. It operates in North America, the Asia Pacific, Europe, the Middle East, and Africa. Volpara Health Technologies Limited has a strategic relationship with RevealDx. The company was incorporated in 2009 and is headquartered in Wellington, New Zealand.

Full VPAHF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this VPAHF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VPAHF vs SCHDVPAHF vs JEPIVPAHF vs OVPAHF vs KOVPAHF vs MAINVPAHF vs DGROVPAHF vs NOBLVPAHF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.